Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Roivant's Newest Company to Develop Ligand's Diabetes Candidate LGD-6972

Roivant Sciences will partner with Ligand Pharmaceuticals to codevelop its type 2 diabetes candidate LGD-6972 through a collaboration that ...

Forward this item to a colleague:

(Separate multiple addresses by commas)